(S)-N-[1-(3-Morpholin-4-ylphenyl)ethyl]-3-phenylacrylamide (2) was synthesized as an orally bioavailable KCNQ2 potassium channel opener. In a rat model of migraine, 2 demonstrated significant oral activity in reducing the total number of cortical spreading depressions induced by potassium chloride.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/jm034073f | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!